United Therapeutics

63 total trials 5 currently recruiting 39 completed

United Therapeutics sponsors 63 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 39 completed. 26 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Arterial Hypertension, with 4 trials.

Trial Pipeline

63 total, page 1 of 2

RECRUITING Phase 1

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

NCT07224763
RECRUITING Phase 1

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

NCT06878560
RECRUITING

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT06388421
RECRUITING Phase 3

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535
RECRUITING

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

NCT05776225
ACTIVE NOT RECRUITING Phase 4

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
ACTIVE NOT RECRUITING

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

NCT03045029
TERMINATED

Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin

NCT05060315
COMPLETED Phase 3

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

NCT04708782
TERMINATED Phase 3

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

NCT04084678
TERMINATED Phase 1

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

NCT03857841
COMPLETED Phase 1

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739
COMPLETED

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

NCT03888365
COMPLETED Phase 4

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

NCT03497689
COMPLETED Phase 3

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688
TERMINATED Phase 3

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

NCT03794583
TERMINATED Phase 3

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

NCT03496623
TERMINATED Phase 3

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

NCT03043651
TERMINATED Phase 3

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580
COMPLETED Phase 2

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03098030
COMPLETED Phase 2

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
TERMINATED Phase 2

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02633293
TERMINATED

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

NCT02693171
TERMINATED Phase 2

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

NCT02261883
COMPLETED Phase 2

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

NCT02279745
COMPLETED Phase 2

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

NCT02276872
COMPLETED Phase 2

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

NCT02279160
COMPLETED Phase 1

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

NCT02318758
COMPLETED Phase 3

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

NCT01560637
COMPLETED Phase 3

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

NCT01934582
COMPLETED

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

NCT01799473
COMPLETED Phase 1

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

NCT01592045
COMPLETED Phase 1

Three Times Daily Dosing of UT-15C

NCT01746485
COMPLETED Phase 3

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

NCT01560624
COMPLETED Phase 2

Remodulin® to Oral Treprostinil Transition

NCT01588405
COMPLETED Phase 2

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

NCT01477333
COMPLETED

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

NCT01028651
COMPLETED

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
COMPLETED Phase 1

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

NCT01172496
COMPLETED Phase 1

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

NCT01153386
COMPLETED Phase 1

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

NCT01165476
COMPLETED Phase 1

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

NCT01131845
COMPLETED Phase 2

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

NCT01104870
COMPLETED Phase 1

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

NCT00963027
COMPLETED Phase 1

Effect of Food on the Pharmacokinetics of Oral Treprostinil

NCT00963001
TERMINATED Phase 2

Open-Label Study of Oral Treprostinil in Digital Ulcers

NCT00848107
TERMINATED Phase 2

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

NCT00969722
COMPLETED Phase 3

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

NCT00887978
COMPLETED Phase 2

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
COMPLETED Phase 1

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

NCT00848939
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 14
Phase 2 14
Phase 3 18
Phase 4 8

Therapeutic Areas

Pulmonary Arterial Hypertension 4
Pulmonary Hypertension 4
Interstitial Lung Disease 3
Xenotransplantation 2
ESRD (End-Stage Renal Disease) 2
Kidney Transplantation 2
Pulmonary Hypertension Due to Lung Diseases and Hypoxia 1
Progressive Pulmonary Fibrosis 1
Healthy 1

What the Pipeline for United Therapeutics Shows

According to the ClinicalTrials.gov registry, United Therapeutics is linked to 63 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting, about 8% of the sponsor's indexed portfolio, and 39 are already marked complete, representing roughly 62% of the total.

The phase mix for United Therapeutics reports 26 late-stage studies (Phase 3 and Phase 4 combined) and 28 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for United Therapeutics is Pulmonary Arterial Hypertension with 4 linked trials, and 8 other condition areas appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.